CCA
RETA

Catalyst Capital Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

Catalyst Capital Advisors’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-85
Closed -$7K – 436
2019
Q3 		$7K Buy
85
+33
+63% +$2.8K ﹤0.01% 378
2019
Q2 		$5K Buy
+52
New +$4.49K ﹤0.01% 398

Other funds holding RETA

CI
CPMG Inc Dallas, Texas $37.1M AUM 74.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Catalyst Capital Advisors's RETA Position: Q4 2019 in Review

Catalyst Capital Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2019, closing a stake of 85 shares — an estimated $7K sold.

Catalyst Capital Advisors first reported a position in RETA in Q2 2019 and held it in 2 quarters. The position peaked at $7K in Q3 2019. 218 funds tracked by Wall St. Rank hold RETA as of Q4 2019.

  • Catalyst Capital Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2019 after selling out during the quarter.
  • Catalyst Capital Advisors sold 85 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2019, an estimated $7K.
  • Catalyst Capital Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q2 2019 and held it in 2 quarters.
  • Catalyst Capital Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $7K in Q3 2019.
  • 218 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2019.

Based on Catalyst Capital Advisors's 13F filing for Q4 2019, filed 6 Feb 2020.